Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients

Internal Medicine

Volumn 47, Issue 19, 2008, Pages 1637-1643

  Hirakawa, Miharu ^a   Ikeda, Kenji ^a   Arase, Yasuji ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis; Cox proportional hazard model; Hepatitis C virus; Hepatocellular carcinoma; Sustained virological response

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC LIVER DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; RISK FACTOR; SEX RATIO;

ADOLESCENT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 56349165583     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1087     Document Type: Article

References (42)

1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter, randomized, controlled trial. N Engl J Med 321: 1501-1506, 1989.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 321: 1506-1510, 1989.
3. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101: 497-502, 1991.
4. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 13: 1040-1043, 1991.
5. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055, 1995.
6. Mazzella G, Accogi E, Scottli S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24: 141-147, 1996.
7. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 26: 128S-132S, 1997.
8. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83: 901-909, 1998.
9. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695, 1998.
10. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351: 1535-1539, 1998.
11. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27: 1394-1402, 1998.
12. Shindo M, Ken A, Okuno T. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy. Cancer 85: 1943-1950, 1999.
13. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan IHIT Study Group. Inhibition of hepatocellular carcinogenesis by interferon Therapy. Ann Int Med 131: 174-181, 1999.
14. Ikeda K, Saitoh S, Kobayashi M, et al. Long-term interferon therapy for 1 year or longer in reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 16: 406-415, 2001.
15. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29: 1124-1130, 1999.
16. Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101: 1616-1622 2004.
17. Toyoda H, Kumada T, Tokuda A, et al. Long-term follow-up of sustained responders to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 7: 414-419, 2000.
18. Ikeda M, Fujiyama S, Tanaka M, et al. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C. J Gastroenterol Hepatol 21: 122-128, 2006.
19. Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 20: 752-758, 2005.
20. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Intern 27: 186-191, 2007.
21. Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 40: 148-156, 2005.
22. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 23: 593-596, 2003.
23. Yamaguchi K, Omagari K, Kinoshita H, et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J Clin Gastroenterol 29: 207-209, 1999.
24. Yamada M, Ichikawa M, Matsubara A, Ishiguro Y, Yamada M, Yokoi S. Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy. Eur J Gastroenterol Hepatol 12: 1029-1032, 2000.
25. Nagano K, Fukuda Y, Nakano I, et al. A case of the development of two hepatocellular carcinomas and a cholangiocarcinoma with cirrhosis after elimination of serum hepatitis C virus RNA with interferon therapy. Hepatogastroenterology 47: 1436-1438, 2000.
26. Yamaura T, Matsumoto A, Rokuhara A, et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J Gastroenterol Hepatol 17: 1229-1235, 2002.
27. Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastroenterol Hepatol 11: 535-539, 1996.
28. Tamori A, Kuroki T, Nishiguchi S, et al. Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 43: 1079-1083, 1996.
29. Hirashima N, Mizokami M, Orito E, et al. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J Gastroenterol Hepatol 11: 955-958, 1996.
30. Miyano S, Togashi H, Shinzawa H, et al. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 14: 928-930, 1999.
31. Inoue M, Ohhira M, Ohtake T, et al. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology 46: 2554-2560, 1999.
32. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435, 1981.
33. Kaplan EL, Meier P. Nonparametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
34. Cox DR. Regression models and life tables. J R Stat Soc 34: 248-275, 1972.
35. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis - A prospective observation of 2215 patients. J Hepatol 28: 930-938, 1998.
36. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis - A prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 18: 47-53, 1993.
37. Kasahara A, Hayashi N, Mochizuki K, et al, The Osaka Liver Disease Study Group. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. J Viral Hepat 7: 343-351, 2000.
38. Yabuuchi I, Imai Y, Kawata S, et al. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 20: 290-295, 2000.
39. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1,148 patients - Viral Hepatitis Therapy Study Group. J Hepatol 30: 653-659, 1999.
40. Ikeda K, Arase Y, Saitoh S, et al. Anti-carcinogenic impact of interferon therapy in patients with chronic hepatitis C-A large-scale long-term study in a single center. Intervirology 49: 82-90, 2006.
41. Benvegnú L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 74: 2442-2448, 1994.
42. Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 89: 1241-1250, 1998.